UNI-MB - logo
UMNIK - logo
 
E-viri
Celotno besedilo
Recenzirano
  • Tian, Xiao-Peng; Huang, Wei-Juan; Huang, Hui-Qiang; Liu, Yan-Hui; Wang, Liang; Zhang, Xi; Lin, Tong-Yu; Rao, Hui-Lan; Li, Mei; Liu, Fang; Zhang, Fen; Zhong, Li-Ye; Liang, Li; Lan, Xiao-Liang; Li, Juan; Liao, Bing; Li, Zhi-Hua; Tang, Qiong-Lan; Liang, Qiong; Shao, Chun-Kui; Zhai, Qiong-Li; Cheng, Run-Fen; Sun, Qi; Ru, Kun; Gu, Xia; Lin, Xi-Na; Yi, Kun; Shuang, Yue-Rong; Chen, Xiao-Dong; Dong, Wei; Sang, Wei; Sun, Cai; Liu, Hui; Zhu, Zhi-Gang; Rao, Jun; Guo, Qiao-Nan; Zhou, Ying; Meng, Xiang-Ling; Zhu, Yong; Hu, Chang-Lu; Jiang, Yi-Rong; Zhang, Ying; Gao, Hong-Yi; He, Wen-Jun; Xia, Zhong-Jun; Wu, Cheng-Lei; Zhang, Mei-Yin; Wang, Hui-Yun; Xie, Dan; Cai, Qing-Qing

    Leukemia, 10/2019, Letnik: 33, Številka: 10
    Journal Article

    New prognostic factors are needed to establish indications for haematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) for T-cell lymphoblastic lymphoma (T-LBL) patients. We used microarray to compare T-LBL tissue samples (n = 75) and fetal thymus tissues (n = 20), and identified 35 differentially expressed miRNAs. Using 107 subjects as the training group, we developed a five-miRNA-based classifier to predict patient survival with LASSO Cox regression: lower risk was associated with better prognosis (disease-free survival (DFS): hazard ratio (HR) 4.548, 95% CI 2.433-8.499, p < 0.001; overall survival (OS): HR 5.030, 95% CI 2.407-10.513, p < 0.001). This classifier displayed good performance in the internal testing set (n = 106) and the independent external set (n = 304). High risk was associated with more favorable response to HSCT (DFS: HR 1.675, 95% CI 1.127-2.488, p = 0.011; OS: HR 1.602, 95% CI 1.055-2.433, p = 0.027). When combined with ECOG-PS and/or NOTCH1/FBXW7 status, this classifier had even better prognostic performance in patients receiving HSCT (DFS: HR 2.088, 95% CI 1.290-3.379, p = 0.003; OS: HR 1.996, 95% CI 1.203-3.311, p = 0.007). The five-miRNA classifier may be a useful prognostic biomarker for T-LBL adults, and could identify subjects who could benefit from HSCT.